Class of Drugs May Raise Risk of Heart Attack

Susan Farley
Published Online: Wednesday, December 1, 2004

Following the revelation that the arthritis drug Vioxx (rofecoxib) may increase its users' risk for heart attack, researchers are finding that the entire cyclooxygenase-2 class of drugs may produce the same adverse effect as Vioxx. The results of previous studies of Celebrex (celecoxib) and Vioxx suggest that the mechanism of action that inhibits inflammation and makes the drug easier on the stomach also may block a certain substance that helps prevent heart problems. Garret FitzGerald, MD, a cardiologist at the University of Pennsylvania who led the present study, believes that the effect is present throughout the entire class of drugs.

In studies published in 1999 and 2001, Dr. FitzGerald and colleagues suggested that, by blocking prostaglandins that lead to inflammation, they were creating heart problems while trying to ease stomach problems. Dr. FitzGerald explained, "There's a good prostaglandin and a bad prostaglandin, as far as the heart is concerned." He said that the suppressing of both types of prostaglandins, in the way that nonsteroidal anti-inflammatory drugs do, actually helps the heart, whereas shutting down only the "good" prostaglandin can raise the risk of high blood pressure, atherosclerosis, and clotting.

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues